{"id":5106,"date":"2011-07-14T20:23:29","date_gmt":"2011-07-14T20:23:29","guid":{"rendered":"http:\/\/crashtext.org\/misc\/hypertension.htm\/"},"modified":"2013-03-16T17:26:11","modified_gmt":"2013-03-16T21:26:11","slug":"hypertension","status":"publish","type":"post","link":"https:\/\/crashingpatient.com\/medical-surgical\/vascular\/hypertension.htm\/","title":{"rendered":"Hypertension"},"content":{"rendered":"
True physio of htn<\/a><\/p>\n cardene<\/p>\n can be given 1\/2-1 cc at a time when diluted to 0.5 mg\/ml<\/p>\n Three categories of ED presentations (Annals 41:1, April 2003; excellent review article):<\/p>\n There is no longer any category for severe increase BP.<\/p>\n <\/p>\n Hypertensive urgencies and emergencies<\/p>\n Patients with marked BP elevations and acute target-organ damage (e.g.,<\/p>\n encephalopathy, myocardial infarction, unstable angina, pulmonary edema,<\/strong><\/p>\n eclampsia, stroke, head trauma, life-threatening arterial bleeding, or aortic<\/strong><\/p>\n dissection<\/strong>) require hospitalization and parenteral drug therapy.<\/p>\n 1 Patients with<\/p>\n markedly elevated BP but without acute target organ damage usually do not<\/p>\n require hospitalization, but they should receive immediate combination oral<\/p>\n 19<\/p>\n antihypertensive therapy. They should be carefully evaluated and monitored<\/p>\n for hypertension-induced heart and kidney damage and for identifiable causes<\/p>\n of hypertension. (See table 4.)<\/p>\n <\/p>\n Hypertensive Crises: Emergencies and Urgencies<\/p>\n Hypertensive emergencies are characterized by<\/p>\n severe elevations in BP (>180\/120 mmHg) complicated<\/p>\n by evidence of impending or progressive target<\/p>\n organ dysfunction. They require immediate<\/p>\n BP reduction (not necessarily to normal) to prevent<\/p>\n or limit target organ damage.<\/p>\n 312,313 Examples<\/p>\n include hypertensive encephalopathy, intracerebral<\/p>\n hemorrhage, acute MI, acute left ventricular<\/p>\n failure with pulmonary edema, unstable angina<\/p>\n pectoris, dissecting aortic aneurysm, or eclampsia.<\/p>\n <\/p>\n Hypertensive urgencies are those situations associated<\/p>\n with severe elevations in BP without progressive<\/p>\n target organ dysfunction. Examples include<\/p>\n upper levels of stage II hypertension associated<\/p>\n with severe headache, shortness of breath,<\/p>\n epistaxis, or severe anxiety. The majority of these<\/p>\n patients present as noncompliant or inadequately<\/p>\n treated hypertensive individuals, often with little<\/p>\n or no evidence of target organ damage.<\/p>\n Early triage to establish the appropriate therapeutic<\/p>\n strategies for these patients is critical to limiting<\/p>\n morbidity and mortality.<\/p>\n 314 Patients presenting<\/p>\n with severe hypertension may represent as<\/p>\n much as 25 percent of all patient visits to busy<\/p>\n urban emergency rooms (ERs).<\/p>\n 315<\/p>\n <\/p>\n Patients with hypertensive emergencies should be<\/p>\n admitted to an intensive care unit for continuous<\/p>\n monitoring of BP and parenteral administration<\/p>\n of an appropriate agent (table 23). The initial<\/p>\n goal of therapy in hypertensive emergencies is to<\/p>\n reduce mean arterial BP by no more than 25 percent<\/p>\n (within minutes to 1 hour), then if stable, to<\/p>\n 160\/100\u0096110 mmHg within the next 2\u00966 hours.<\/p>\n Excessive falls in pressure that may precipitate<\/p>\n renal, cerebral, or coronary ischemia should be<\/p>\n avoided. For this reason, short-acting nifedipine<\/p>\n is no longer considered acceptable in the initial<\/p>\n treatment of hypertensive emergencies or urgencies.<\/p>\n If this level of BP is well tolerated and the<\/p>\n patient is clinically stable, further gradual reductions<\/p>\n toward a normal BP can be implemented<\/p>\n in the next 24\u009648 hours. There are exceptions<\/p>\n to the above recommendation\u0097patients with an<\/p>\n ischemic stroke in which there is no clear evidence<\/p>\n from clinical trials to support the use of immediate<\/p>\n antihypertensive treatment, patients with<\/p>\n aortic dissection who should have their SBP lowered<\/p>\n to <100 mmHg if tolerated, and patients in<\/p>\n whom BP is lowered to enable the use of thrombolytic<\/p>\n agents (see Stroke).<\/p>\n <\/p>\n Some patients with hypertensive urgencies may<\/p>\n benefit from treatment with an oral, short-acting<\/p>\n agent such as captopril, labetalol, or clonidine followed<\/p>\n by several hours of observation. However,<\/p>\n there is no evidence to suggest that failure to<\/p>\n aggressively lower BP in the ER is associated with<\/p>\n any increased short-term risk to the patient who<\/p>\n presents with severe hypertension. Such a patient<\/p>\n may also benefit from adjustment in their antihypertensive<\/p>\n therapy, particularly the use of combination<\/p>\n drugs, or reinstitution of medications if<\/p>\n noncompliance is a problem. Most importantly,<\/strong><\/p>\n patients should not leave the ER without a confirmed<\/strong><\/p>\n followup visit within several days.<\/strong><\/p>\n <\/p>\n Unfortunately, the term \u0093urgency\u0094 has led to<\/p>\n overly aggressive management of many patients<\/p>\n with severe, uncomplicated hypertension.<\/p>\n Aggressive dosing with intravenous drugs or even<\/p>\n oral agents, to rapidly lower BP is not without<\/p>\n risk. Oral loading doses of antihypertensive<\/p>\n agents can lead to cumulative effects causing<\/p>\n hypotension, sometimes following discharge from<\/p>\n the ER. Patients who continue to be noncompliant<\/p>\n will often return to the ER within weeks.<\/p>\n <\/p>\n Causes of hypertensive crises <\/strong> \u0095 Abrupt increase in BP in patients with chronic hypertension \u0095 Renovascular hypertension\/renal disease \u0095 Withdrawal from antihypertensive drugs \u0095 Drug-induced hypertension (eg, amphetamines, diet pills, tricyclic antidepressants, street drugs [eg, cocaine]), drug withdrawal, pheochromocytoma \u0095 Preeclampsia\/eclampsia \u0095 Head injury of any kind \u0095 Vasculitis \u0095 Scleroderma and other collagen-vascular diseases<\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/a><\/a><\/p>\n The blood pressure at triage does not correlate with bps taken under AHA reference conditions (Academic Emergency Medicine Volume 11, Number 3 237-243)<\/p>\n Take BP in both arms, and before and after evaluation to get true reading<\/p>\n Examine fundi for retinal hemorrhage and papilledema<\/p>\n Signs of Heart Failure<\/p>\n Creatinine and UA for protein and blood.\u00a0 Urine dipstick totally normal rules out clinically\u00a0 significant creatnine elevation\u00a0 (AEM 2002 9:1)\u00a0 Signs of acute damage are large numbers of red cells and red cell casts<\/p>\n <\/p>\n unfortunately 2nd study showed 82% sends 34% spec (Am J Emerg Med.<\/a>\u00a02010 Jun;28(5):613-6)<\/p>\n EKG<\/p>\n Numbers don’t matter, only whether there is end-organ damage or not (Journal of Hypertension Issue: Volume 30(5), May 2012, p 882\u2013883)<\/p>\n Screening tests probabl are very low yield (Ann Emerg Med 2008;51:231)<\/p>\n <\/p>\n <\/a><\/a><\/a><\/p>\n patients prescribed short-acting nifedipine (which result sin precipitious drops in BP) had a much higher stroke rate (Neurology 2011;77:1229\u20131234)<\/p>\n nitroprusside is the traditional first choice (beware in renal and liver failure), but labetalol is quickly becoming a more attractive option.\u00a0 Aim to reduce MAP by 30-40% over the first two hours.<\/p>\n Labetalol is more potent at beta that at alpha 1 adrenoceptors in man; the ratio of beta-alpha antagonism is 3:1 after oral and 6.9:1 after intravenous administration. (Pharmacotherapy. 1983 Jul-Aug;3(4):193-219.)<\/p>\n <\/p>\n Start 5 mg\/hr (50 cc\/hr)<\/p>\n Increase infusion by 2.5 mg\/hr (25 cc\/hr)<\/p>\n Dosage should not exceed 15 mg\/hr (150 cc\/hr)<\/p>\n For rapid control, change every 5 minutes<\/p>\n For gradual control, change every 15 minutes<\/p>\n <\/p>\n For rapid control, decrease rate to 3 mg\/hr (30 cc\/hr)<\/p>\n For gradual control, maintain current infusion rate<\/p>\n <\/p>\n Clue RCT nicardipine vs. labetalol (Crit Care 2011;15:R157)<\/p>\n more likely to reach goal < 30 min<\/p>\n <\/p>\n <\/p>\n cyanide is converted to thiocyanate in the liver using substrate of thiosulfate<\/p>\n increased anion gap acidosis is late sign of toxicity<\/p>\n treat with thiosulfate or hydroxocobalamin<\/p>\n Autoregulation of cerebral blood flow is altered in patients with hypertension particularly in the setting of underlying cerebrovascular disease such that even slight decreases in blood pressure increase the risk of a cerebral ischemic event. The National Institute of Neurologic Disorders and Stroke (NINDS) recommends deferral of treatment of systolic pressures of 185-220mm Hg and\/or diastolic pressures of 105-120mm Hg in the absence of other clear indications for immediate intervention.\u00a0 (J Emerg Med 19(4):339, 2000)<\/p>\n AHA recommendations for hemorrhagic stroke is to treat MAP>130 or SBP> 220.\u00a0 Nimodipine is to prevent vasospasm not to treat the BP.<\/p>\n Most commonly occurs in young black males with renal parenchymal disease or renovascular disease.\u00a0 Ocular findings will be present on fundoscopic exam.\u00a0 Papilledema is the sine qua non of malignant hypertension.\u00a0 If it is absent, then it is accelerated hypertension, but the prognosis is just as bad.\u00a0 Treatment should begin immediately.<\/p>\n Triad of htn, altered mental status and papilledema (often) heralds this condition.\u00a0 This state is most likely to occur in previously normotensive patients whose cerebral autoregulatory system is not prepared for the precipitous rise in BP.\u00a0 A CT scan will show characteristic changes.<\/p>\n Renal Artery Stenosis-young white women get medial fibroplasia of renal arteries.\u00a0 Can also be seen in blacks and whites often with rapidly progressive disease.\u00a0 ACEI may cause improvement with unilateral stenosis, but failure in bilat.<\/p>\n Glomerulonephritis-IgA (#1 cause), post-Strep<\/strong>, Henoch-Schoenlein Purpura<\/p>\n will have elevated renin<\/p>\n need to give high dose ACEIs<\/p>\n From 20 weeks gestation till 2 weeks postpartum<\/p>\n sympathomimetics, MAO interactions<\/p>\n <\/p>\n Tachy, HA, hypertension, check urine metanephrine, serum catecholamines<\/p>\n Give IV phentolamine<\/p>\n associated with neurofibromatosis<\/p>\n <\/p>\n Although measurement of plasma free metanephrine levels has been recently advocated by some groups, 24-hour urinary catecholamine levels and total metanephrine level have consistently proven to be the most specific tests available for the diagnosis of phaeochromocytoma.5,10 Elevations in the level of one or more of these analytes (above the 95% reference range designated as the upper limit of normal by laboratories) are common in patients with paroxysmal symptoms or poorly controlled hypertension not due to phaeochromocytoma. Thus, we recommend that higher cut-off values, roughly two times the upper limit of normal for most laboratories, be used to identify patients suitable for further workup. Repeat biochemical testing 6 weeks after stopping drugs likely to confound the results is ideal, and tests performed during major physical or psychological stress should be interpreted with extreme caution (if performed at all). It is important to note that alterations in plasma catecholamine levels may be caused not only by medications, but also by the underlying diseases being treated (eg, major depression in the case of tricyclic antidepressants or severe heart disease in the case of \u03b2-blockers).11-13 All patients should undergo at least two 24-hour urine collections for measuring levels of catecholamines and their metabolites. Clonidine suppression testing \u0097 the measurement of plasma free normetanephrine before and after the oral administration of 0.3 mg clonidine \u0097 is highly sensitive and specific, and may be a useful adjunct in patients with more than one prior set of equivocal tests.6 (eMJA)<\/p>\n Medications and conditions that may cause false positive results of biochemical tests for phaeochromocytoma<\/p>\n Medication or condition<\/p>\n Test(s) confounded<\/p>\n Tricyclic antidepressants<\/p>\n Urinary catecholamines and metanephrines, plasma free metanephrines<\/p>\n Clozapine<\/p>\n Urinary catecholamines and metanephrines<\/p>\n Phenoxybenzamine<\/p>\n Plasma free metanephrines<\/p>\n Calcium channel blockers<\/p>\n Plasma noradrenaline, urinary noradrenaline, urinary adrenaline<\/p>\n \u03b2-adrenergic blockers<\/p>\n Urinary catecholamines and metanephrines, plasma free metanephrines (minor effect)<\/p>\n \u03b11-adrenergic blockers<\/p>\n Urinary noradrenaline<\/p>\n Sympathomimetics<\/p>\n Urinary catecholamines and metanephrines, plasma free metanephrines<\/p>\n Buspirone<\/p>\n Urinary metanephrines<\/p>\n Major physical or psychological stress*<\/p>\n Urinary catecholamines and metanephrines, plasma free metanephrines<\/p>\n * Hypoglycaemia, hypoxia, hypovolaemia, stroke, surgery, myocardial infarction, heart failure, severe pain, depression, panic disorder, sleep apnoea.<\/p>\n <\/p>\n <\/p>\n Draw tube for renin and aldosterone<\/p>\n <\/p>\n NIH’s ALLHAT study shows equal effectiveness between thiazide diuretic (chlorthalidone), lisinopril, and amlodipine for the prevention of MIs and coronary death.\u00a0 The diuretic was more effective at preventing heart failure and more effective than amlodipine at preventing stroke.\u00a0 The ALLHAT study included more minorities than a recent Australian study which showed ACEI are better.\u00a0 Probably the best choice is an ACEI and a diuretic for double therapy in all comers.<\/p>\n Antihypertensive Agents<\/p>\n Loop Diuretics<\/p>\n furosemide (1) to bumetanide (40) to torsemide (4)<\/p>\n synergistic increase in auditory toxicity of aminoglycosides<\/p>\n electrolyte disturbances<\/p>\n NSAIDS reduce efficacy by blocking prostaglandin synthesis<\/p>\n Thiazides<\/p>\n Can precipitate or exacerbate hyperglycemia in diabetics and prediabetics<\/p>\n captopril is solely cleared by kidneys<\/p>\n Iron supplementation inhibits cough associated withACE inhibitors. (Hypertension. 2001 Aug;38(2):166-70.)<\/p>\n <\/p>\n <\/p>\n <\/p>\n There is a lack of relationship between symptoms and hypertension (Am J Emerg Med 2005;23(2):106)<\/p>\n <\/p>\n <\/p>\n <\/p>\n ACEP Clinical Policy<\/p>\n <\/p>\n Patient Management Recommendations: Do asymptomatic patients with elevated blood pressures benefit from rapid lowering of their blood pressure? Level A recommendations None specified. Level B recommendations 1 Initiating treatment for asymptomatic hypertension in the ED is not necessary when patients have follow-up. 2 Rapidly lowering blood pressure in asymptomatic patients in the ED is unnecessary and may be harmful in some patients. 3 When ED treatment for asymptomatic hypertension is initiated, blood pressure management should attempt to gradually lower blood pressure and should not be expected to be normalized during the initial ED visit. Level C recommendations None specified. Annals of Emergency Medicine Volume 47, Issue 3 , March 2006, Pages 237-249<\/p>\n <\/p>\n <\/p>\n Once these are considered and ruled out, management should include fluid replacement with normal saline and blood pressure reduction. Why the former? Hypertensive emergencies cause a pressure induced natriuresis by increasing the forces exerted on the renal afferent arterioles. The increased pressure activates the rennin\/angiotensin\/aldosterone system, causing diuresis and volume depletion, which can be easily corrected. Administration of saline may cause a decrease in blood pressure by itself before institution of blood pressure lowering medication. Pressure reduction should aim for a 25% reduction in the first two hours, 15% in the first, and 10% in the second. But don\u0092t overshoot! A 40% reduction in blood pressure will lead to its own neurologic event. Use titratable meds only to achieve the lowered pressure. Sublingual, transdermal, and oral meds can cause a precipitous decline and can\u0092t be reversed.<\/p>\n <\/p>\n Headache in patients with mild to moderate hypertension is generally not associated with simultaneous blood pressure elevation Abstract<\/strong> Objective: Although headache is regarded a symptom of hypertension, its relation to blood pressure, especially in mild and moderate hypertension, is not clear. Thus, the aim of the study was to investigate whether headache in patients with mild to moderate hypertension may be attributed to simultaneous elevations in blood pressure.Design and methods: Ambulatory blood pressure monitoring (ABPM) was performed in patients (mean age 48 \u00b1 10 years, n<\/em> = 150, 92 men, 58 women) classified, according to their office blood pressure, as stage 1-2 hypertensives (JNC VI). Headache periods were recorded in patients’ diaries. Results: Headaches were generally not directly associated with blood pressure elevations in the studied group of stage 1-2 hypertensive patients because (i) blood pressure values from headache periods were not significantly higher than those from headache-free periods; (ii) blood pressure values directly preceding the pain were not significantly different from values at the beginning of headache; and (iii) in the vast majority of hypertensives, their maximal blood pressure values were recorded during headache-free periods. Moreover, in some instances, patients who showed maximal ABPM values during headache had relatively high blood pressure, i.e. \u0084 180\/110 mmHg.Conclusions: Our results did not support the opinion that headache experienced by stage 1-2 hypertensives was generally caused by simultaneous elevation in blood pressure. The direct mechanisms of headache in hypertension, as well as the relation between increments in blood pressure above 180\/110 mmHg and headache, need further investigations.<\/p>\n <\/p>\n Lisa Cohen recently summarized rare “genetic” forms of hypertension including Liddle’s syndrome and PHA type II (Gordon’s syndrome). The most common forms of secondary hypertension are:<\/p>\n Typically others causes such as CKD or sleep apnea are not considered “secondary” forms of hypertension. Physical and laboratory findings can help and guide in ruling out secondary forms of hypertension: If you find this -> think this !!!<\/p>\n Last but not least, a few more facts on the three most common secondary forms of hypertension:<\/p>\n <\/p>\n transdermal GTN (5 mg) or control lowered peripheral systolic BP by (mean) 23 mm Hg (95% CI, 2 to 45; (Hypertension. 2006;47:1209-1215.)<\/p>\n","protected":false},"excerpt":{"rendered":" Array<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[30],"tags":[],"yoast_head":"\n<\/span>Systemic Hypertension<\/span><\/h2>\n
\n
<\/span>JNC VII<\/span><\/h2>\n
Clinical Examination<\/h4>\n
<\/span>Testing<\/span><\/h3>\n
<\/span>Precipitious Drops in BP<\/span><\/h2>\n
<\/span>Drugs for HTN Emergency<\/span><\/h2>\n
<\/a><\/h4>\n
Labetalol<\/h4>\n
Nicardipine<\/h4>\n
Nitroprusside<\/h4>\n
Cerebrovascular Emergencies<\/h4>\n
Accelerated-Malignant Hypertension<\/h4>\n
Hypertensive Encephalopathy<\/h4>\n
<\/span>Secondary Hypertension<\/span><\/h3>\n
Acute Renal Disease<\/h4>\n
Scleroderma-Induced Renovascular Hypertension<\/h4>\n
Preeclampsia<\/h4>\n
Toxicologic Ingestions<\/h4>\n
Coarctation of the Aorta<\/h4>\n
Pheochromocytoma<\/h4>\n
\n
\nHyperaldosteronism<\/h4>\n
Withdrawal<\/h4>\n
<\/span>Outpatient Treatment<\/span><\/h2>\n
ACEI<\/h4>\n
<\/span>Headache<\/span><\/h2>\n
<\/span>From Renal Fellow Network<\/span><\/h2>\n
<\/span> Secondary forms of hypertension<\/a><\/span><\/h3>\n
\nI want to summarize other causes of “secondary” hypertension which are not inherited (at least not typically in a Mendelian transmission) and which are potentially “fixable”. These phenotypes are distinct from primary hypertension which affects the vast majority of our patients. Secondary forms of hypertension affect typically less then <5% of patients with hypertension.
\nIn order to identify a reversible cause for hypertension following data needs to be obtained:<\/p>\n\n
\n
\n
\n
\n-Suspect in patients with unexplained low K+
\n-Main causes are adrenal adenomas (~ 70%) and b\/l adrenal hyperplasia (~ 25%)
\n-Screening by checking stimulated PRA or PRC which will be undectable or low
\n-Confirm screening tests with salt\/fluid loading -> “elevated” Aldo level will NOT be suppressed<\/li>\n
\n-Rare tumors arising from chromaffin tissue of the adrenal gland
\n-90% occur in the adrenal medulla
\n-10% are b\/l, 10% are malignant and 10% are familial!
\n-Associated with MEN II
\n-Remember that 33-50% of patients have sustained hypertension !
\n-Suspect it if refractory to treatment
\n-Screen for serum or urine metanephrines
\n-CT adrenals or\/and MIBG scan (meta-iodo-benzyl-guanidine) to detect tumors<\/li>\n<\/ol>\n